ArticlePDF Available

Expression of inducible and neuronal nitric oxide synthase in 20-methyl cholanthrene (20-MCA) induced fibrosarcoma

Authors:

Abstract and Figures

Objective: Studies have shown that expression and localisation of nitric oxide synthase (NOS) depends on the type and differentiation status of different types of tumours. The present study was conducted to evaluate the expression of NOS in carcinogen induced tumour. Method: Swiss albino mice were injected with 20-methyl cholanthrene. Seventy six percent of the animals were positive for fibrosarcoma at the end of 100 days following exposure. The tumours were excised when they reached a predetermined size and immunostained for inducible and neuronal NOS. The staining was graded on an increasing intensity scale. Results: The tumour sections stained very strongly for iNOS as compared to controls (identical sections from tumour negative mice). Weak staining was detected for nNOS in the tumour sections unlike controls. Conclusions: NO may be involved in carcinogen induced fibrosarcoma as seen from the expression of its synthesising enzymes.
Content may be subject to copyright.
NOS EXPRESSION IN FIBROSARCEOMA
Indian Journal of Pharmacology 1999; 31: 315-318 SHORT COMMUNICATION
Correspondence: S.K. Gupta
EXPRESSION OF INDUCIBLE AND NEURONAL NITRIC OXIDE SYNTHASE IN
20-METHYL CHOLANTHRENE (20-MCA) INDUCED FIBROSARCOMA
S.SENGUPTA 1, M.SANYAL 2, V.KOCHUPILLAI 3, S.K.GUPTA 1
Departments of 1Pharmacology, 2Biochemistry, 3Institute Rotary Cancer Hospital,
All India Institute of Medical Sciences, New Delhi 110029.
Manuscript Received: 19.3.99 Revised: 18.4.99 Accepted: 24.5.99
Objective:
Studies have shown that expression and localisation of nitric oxide synthase (NOS) depends
on the type and differentiation status of different types of tumours. The present study was conducted
to evaluate the expression of NOS in carcinogen induced tumour.
Method:
Swiss albino mice were injected with 20-methyl cholanthrene. Seventy six percent of the
animals were positive for fibrosarcoma at the end of 100 days following exposure. The tumours were
excised when they reached a predetermined size and immunostained for inducible and neuronal NOS.
The staining was graded on an increasing intensity scale.
Results:
The tumour sections stained very strongly for iNOS as compared to controls (identical
sections from tumour negative mice). Weak staining was detected for nNOS in the tumour sections
unlike controls.
Conclusions:
NO may be involved in carcinogen induced fibrosarcoma as seen from the expression of
its synthesising enzymes.
Nitric oxide nNOS iNOS 20MCA carcinogenesis fibrosarcoma mice
SUMMARY
INTRODUCTION
Since the discovery of nitric oxide (NO), an endo-
genously generated molecule 1, has been implicated
in diverse physiological roles including intracellular
signalling, as a transcellular messenger or as a cyto-
toxic agent 2,3. It is synthesised by the enzyme nitric
oxide synthase (NOS) in the arginine to citrulline
pathway. Of the three isoforms of NOS, endothelial
NOS (eNOS) and neuronal NOS(nNOS) are consti-
tutive calcium dependent enzymes while inducible
NOS (iNOS) is expressed in response to immuno-
logic stimuli and is capable of sustained NO release
at concentrations which could be cytostatic or cyto-
toxic3.
Studies have demonstrated the presence of NOS in
human tumours4. Cobb’s
et al
suggested that NO pro-
duction could be associated with pathophysiological
processes important to tumourogenesis5. To the best
of our knowledge, no studies have however been con-
ducted to implicate NO in carcinogen induced
cancer. The present study was thus conducted to
evaluate the involvement of NO in carcinogenesis.
MATERIALS AND METHODS
Swiss albino mice (body wt 15-16g, either sex) were
procured from the Central Experimental Animal Facil-
ity of AIIMS and housed 5 per cage with food and
water available
ad libitum
. They were acclimatised in
standard controlled laboratory conditions for 1 week
prior to inclusion in the experiment. On the day of the
experiment all the mice were injected subcutaneously
in the left flank with 20MCA (Sigma, USA) at a dose
of 2mg/kg, in DMSO (Sigma, USA) as vehicle. They
were then housed in sterile conditions and observed
daily until the tumours were palpable. The animals
were sacrificed under chloroform anaesthesia when
the tumours reached a size of 5 x1000 cu mm and
the tumours were immediately excised. Half of the
tumour was processed for H&E staining after fixing
in 10% formalin. The other half was fixed in 4%
KEY WORDS
S. SENGUPTA
et al.
Figure 1. (a) Cross section of the tumour (H&E) at an early stage. The transformed cells can be seen infiltrating the underlying
muscles. (b) Fully developed tumour (5000 cu mm) with H&E staining showing classical Herring bone pattern characteristic
of fibrosarcoma (4X).(c) Negative control tissue stained for iNOS seen at higher magnification and (d) tumour cross section
stained for iNOS with intense staining in the cancer tissues (open arrows). Note the dark stained infiltrated macrophages
stained positively for iNOS (closed arrows). (e) Negative control tissue stained for nNOS at higher power vs (f) positive
nNOS staining in the tumour sections (open arrows) (4X).
Immuno-histocytochemistry
The sections were treated with 70% methanol con-
taining 0.1% H2O2 for a period of 20-30 min to block
endogenous peroxidase activity. Sections were
washed thoroughly and then treated with 20% nor-
mal horse serum (for those to be incubated with
mouse monoclonal antibody) and 20% normal goat
serum (for sections to be titrated with rabbit polyclonal
antibodies) for 3h at 4oC.
The sections were incubated for 3 days at 4oC with
primary antibodies against iNOS (1:50 mouse
monoclonal, Transduction laboratories, Kentucky, USA)
and nNOS(1:250, rabbit polyclonal, Transduction labo-
ratories, Kentucky, USA). The antibodies were diluted
in 0.01M phosphate buffer saline containing 0.5%
Triton X and 5% normal sera. Following this the sec-
tions were washed in buffer and put in secondary
paraformaldehyde in 0.1M phosphate buffer for 2-4 h
at 4o C. After several washes in buffer they were
cryoprotected in 30% sucrose overnight. Sections were
cut at 5-10 µµ
µµ
µm thickness in a Reichart jung cryostat
and stored in vials containing phosphate buffer at
4o C till use for immunohisto-cytochemistry. However,
6 mice did not develop any tumour till day 150 when
they were sacrificed and the tissue was excised from
the left flank and subjected to the same treatment as
above. Of the 25 mice injected with 20-MCA, 6 mice
were put in control group since they did not develop
tumour and rest 19 were put into the other group con-
sidered as tumour group.
H&E staining
Tissue samples were stained with haematoxylin and
eosin according to standard protocol following par-
affin embedding.
a
b
c
d
e
f
316
NOS EXPRESSION IN FIBROSARCEOMA
antibodies (1:200) for 5-6h at 4oC. For iNOS the sec-
ondary antibody was horse anti-mouse IgG (Vector
labs, USA) whereas for nNOS it was goat anti-rabbit
IgG (Vector labs , USA). After washing , the sections
were treated with avidin-biotin peroxidase complex
(Vector Labs, USA) for 2 h at room temperature. For
visualisation of the antigen antibody reactions the sec-
tions were treated with 0.05M acetate-imidazole buffer
(pH 7.4) containing 0.3% nickel sulphate as intensi-
fier, for 15-20 seconds. The sections were finally
rinsed in distilled water, mounted on gelatin coated
slides and air dried. They were then dehydrated in
alcohol and mounted in DPX. The slides were exam-
ined by an independent observer and the intensity of
staining was graded as - when there was no detect-
able staining and grades +, +, ++, +++ were used for
weak, moderate, strong and intense staining respec-
tively. The observer was exposed to control slides
from untreated sections to establish a baseline zero
prior to the sections from negative and positive groups.
RESULTS
Of the 25 animals injected with 20MCA, 19 devel-
oped solid tumours characteristic of fibrosarcoma
with Herring bone pattern (Figures 1a and b). The tu-
mours reached 200 cu mm between day 90-100 and
5000cu mm within 18+2 days after reaching 200 cu
mm, characteristically following a Gompertzian curve.
The remaining 6 mice did not develop tumours even
after 150 days of administration of 20MCA and served
as negative controls. The tumour sections stained
very strongly for iNOS (Figure 1d) and was infiltrated
with macrophages, which was not detected in con-
trol sections (Figure 1c). Neuronal NOS expression
was also significantly elevated (Figure 1f) in com-
parison to controls (Figure 1e). Table 1 gives the gra-
dation of intensity of staining by an independent ob-
server.
DISCUSSION
Nitric oxide (NO) has been implicated in a wide range
of biological functions. It is generated enzymatically
from terminal guanidinonitrogen of L-Arginine by
NOS. Despite intensive investigations, the role of NO,
either as a primary product of LArginine/NOS path-
way or provided by donors, in carcinogenesis and
tumour cell growth remains unclear. NO and its de-
rivatives can cause DNA damage6 and cell death7 at
Table 1. Staining intensity grades for immunostaining in tumour
sections vs control
Immunostaining
Tissue iNOS nNOS
Control (n=6) - -
Tumour (n=19) +++ ++
- no detectable staining , + weak, + moderate, ++ strong,
+++ intense staining
higher concentrations and may exert opposite effects
at lower concentrations8. Growth of solid tumours is
regulated by interactions of endothelial cells of tu-
mour vasculature, the tumour cells and the infiltrat-
ing immune cells as macrophages9. Most of these
cellular components have been shown to generate
NO
in vitro
10,11. Indeed in the present study we found
a significant expression of iNOS in macrophages that
had infiltrated into the tumour tissue. However as
reported in other types of tumours12,13, in the present
study fibrosarcoma induced by carcinogen 20MCA
also had a high expression of iNOS unlike the con-
trol group which did not develop any tumour. This in-
dicates that NO synthesised by iNOS does play a
role in the process of tumourogenesis. Studies have
shown that iNOS transfected cells proliferate at a
slower rate indicating that NO exerts a cytostatic ef-
fect on tumour cells14 but it has been found to pro-
mote solid tumours by promoting angiogenesis12. In
the present study too a high degree of vascularisa-
tion was noted in the tumours; however further ex-
periments are warranted to implicate iNOS synthe-
sised NO in angiogenesis in this tumour type.
The surprising observation was the expression of
nNOS in the tumour section. Luck
et al
15 have shown
that nNOS system is of relevance to myogenic dif-
ferentiation and it is present at an elevated level in
inflammatory myopathies16. The expression of nNOS
in the present system could thus indicate the differ-
entiation, muscle cell death or apoptosis occurring
in the tumour. This suggests that both the isoforms
of NOS have a significant role in the process of
carcino/tumourigenesis. The present study thus opens
the door for further pharmacological experiments with
selective inhibitors of NOS with the possibility of in-
hibiting/altering the progress of the pathology. Indeed
early results have shown that cancer prevention by
317
S. SENGUPTA
et al.
curcumin could be related to inhibition of NOS gene17
or that administration of NG-nitro-L-arginine-methyl-
ester (L-NAME) a NOS inhibitor could reduce the
incidence and number of metastasis18.
ACKNOWLEDGEMENT
SS would like to thank AIIMS for the award of Geeta
Mittal gold medal for basic research in oncology as
the present paper formed part of the material on which
the award was made.
REFERENCES
1. Palmer RM, Ferrodge AG, Moncada S. Nitric oxide re-
lease accounts for the biologic activity of endothelium
derived relaxing factor.
Nature
1987;327:524-6.
2. Moncada S, Palmer RM, Higgs BA. Nitric oxide: physiol-
ogy, pathophysiology and pharmacology.
Pharmacol Rev
1991;43:109-42.
3. Knowles RG, Moncada S. Nitric oxide synthase in mam-
mals.
Biochem J
1994;298:249-58.
4. Thomsen LL, Lawton FG, Knowles RG, Beesley JE,
Riveros-Moreno V, Moncada S. Nitric oxide synthase ac-
tivity in human breast cancer.
Br J Cancer
1995;72:41-4.
5. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA.
Expression of nitric oxide synthase in human central nerv-
ous system tumour.
Cancer Res
1995;55:727-30.
6. Gal A, Wogan GN .Mutagenesis associated with nitric ox-
ide production in transgenic SJL mice.
Proc Natl Acad Sci
USA
1996;93:15102-7.
7. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico
G, Finazzi-Agro A. S-nitrosylation regulates apoptosis.
Na-
ture
1997;388:432-3.
8. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits
apoptosis by preventing increases in caspase-3-like activ-
ity via two distinct mechanisms.
J Biol Chem
1997;
272:31138-48.
9. Sutherland RM, Rasey JS, Hill RP. Tumor biology.
Am J
Clin Oncol
1988;11:253-74.
10. Radomski MW, Jenkins DC, Holmes L, Moncada S. Hu-
man colorectal adenocarcinoma cells: differential nitric
oxide synthesis determines their ability to aggregate plate-
lets.
Cancer Res
1991;51:6073-8.
11. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski
MW, Moncada S. Human colon cancer cell lines show a
diverse pattern of nitric oxide synthase gene expression
and nitric oxide generation.
Br J Cancer
1994;70:847-9.
12. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes
LS,
et al
. Roles of nitric oxide in tumor growth.
Proc Natl
Acad Sci USA
1995;92:4392-6.
13. Thomsen LL, Sargent JM, Williamson CJ, Elgie AW. Nitric
oxide synthase activity in fresh cells from ovarian tumour
tissue: relationship of enzyme activity with clinical param-
eters of patients with ovarian cancer.
Biochem Pharmacol
1998;56:1365-70.
14. Hibbs JB, Taintor RR, Vavrin Z, Granger DL, Drapier JC,
Lancaster JR Jr. in Nitric Oxide from l-Ariginine:a bioregu-
latory system. Eds moncada s and Higgs EA. Amster-
dam,
Elsevier.
1990:pp189-223.
15. Luck G, Oberbaumer I, Blottner D.
In situ
identification of
neuronal nitric oxide synthase (NOS-I) mRNA in mouse
and rat skeletal muscle.
Neurosci Lett
1998;246:77-80.
16. Tews DS, Goebel HH . Cell death and oxidative damage
in inflammatory myopathies.
Clin Immunol Immunopathol
1998;87:240-7.
17. Chan MMY, Huang HI, fenton MR, Fong d.
In vivo
inhibi-
tion of nitric oxide synthase gene expression by curcumin,
a cancer preventive natural product with anti-inflamma-
tory properties.
Biochem Pharmacol
1998;55:1955-62.
18. Iwasaki T, Higashiyama M, Kuriyama K, Sasaki A, Mukai
M,
et al
. NG-nitro-L-arginine methyl ester inhibits bone
metastasis after modified intracardiac injection of human
breast cancer cells in a nude mouse model.
Jpn J Cancer
Res
1997;88:861-6.
318
... Staining results were interpreted according to the scheme reported by previous authors. 21,22 ...
... Staining results were interpreted according to the scheme reported by previous authors. 21,22 ...
Article
Full-text available
The aim of this study was to investigate the effects of Nigella sativa (NS) fixed oil in comparison to dexamethasone (Dex) on inducible nitric oxide synthase (iNOS), peripheral blood eosinophils (PBE), allergen specific serum IgG1 and interleukins and airway inflammation in a murine model of allergic asthma. Thirty-one mice were divided into four groups. Group I (n = 6) served as the control group. Group II (n = 10) mice were sensitized intraperitoneally and challenged intratracheally with cone albumin with no treatment. Group III(n = 6) mice were sensitized, challenged, and treated with Dex for 17 days starting at 24 hours after the first challenge. Group IV (n = 9) mice were sensitized, challenged, and treated with NS fixed oil for 17 days as well. For all groups, the following procedures were carried out: immunohistochemical study of iNOS in lung tissues, detection of PBE percentage, and histopathological examination of lung tissues for inflammatory cells. Lung tissue iNOS expression increased in sensitized, non-treated mice compared with controls, but this increase was not significant. NS fixed oil treatment significantly reduced PBE and lung inflammation but did not significantly reduce lung tissue iNOS expression compared with the control group. These effects were comparable to the effects of Dex. These results suggest that Nigella sativa exhibits immunomodulatory and antiinflammatory effect which may be useful for treatment of allergic asthma.
Article
Full-text available
The existence and role of an L-arginine:nitric oxide (NO) pathway in two human colorectal adenocarcinoma cell lines, SW-480 and SW-620, were investigated. Both cell lines, which derive from the same patient, SW-480 from the primary tumor and SW-620 from its metastatic lesion, were shown to have a cytosolic, Ca(2+)-independent, NADPH-dependent NO synthase, the activity of which was lower in the cytosol of SW-620. These cells were more potent inducers of platelet aggregation. In contrast, SW-480, which had more NO synthase activity, were less potent inducers of platelet aggregation. Pretreatment of both cell lines with NG-monomethyl-L-arginine, an inhibitor of NO synthase, potentiated their proaggregating effect and made them equally active. Exogenous L-arginine, NO, and related nitrovasodilators all inhibited platelet aggregation induced by SW-620. The antiaggregating activity of NO was further potentiated by prostacyclin and by M&B22948, a selective inhibitor of cyclic GMP phosphodiesterase. We propose that the generation of NO by tumor cells inversely correlates with their metastatic potential. Furthermore, we show that the lower activity of NO synthase in metastatic cells is due to the presence in these cells of a low molecular weight inhibitor of the NO synthase. In addition, agents which modulate platelet function by a cyclic GMP-dependent mechanism may be useful in the prevention of tumor metastasis.
Article
Full-text available
Nitric oxide is generated by the NO synthases, a family of isoenzymes expressed in a wide range of mammalian cells. In the vascular and nervous systems distinct isoforms generate NO to act as a signal transduction mechanism. The isoform induced by cytokines, on the other hand, provides a sustained release of NO which mediates some cytotoxic and cytostatic effects of the immune system. Solid tumors are a heterogeneous population of cell types, including tumor, vascular, and infiltrating immune cells. Studies in vitro show that NO synthase can be present in many of these cells. However, its presence in situ in solid human tumors has not been reported. In this study, we have investigated NO synthase activity and its cellular localization in malignant and nonmalignant human gynecological tissue. Nitric oxide synthase activity was observed in malignant tissue, was highest (> or = 250 pmol/min/g tissue) in poorly differentiated tumors, and was below detectable levels in normal gynecological tissue. Furthermore, investigations with a polyclonal NO synthase antibody revealed immunoreactivity only in malignant tissue. This was associated with NO synthase activity and localized to tumor cells. Thus NO synthase is present in human gynecological tumors, and its presence seems to correlate inversely with the differentiation of the tumor.
Article
Full-text available
A panel of human colonic adenocarcinoma cell lines was examined both for expression of mRNAs of the nitric oxide synthase (NOS) gene family and for evidence of enzymic activity based on citrulline and nitrite (NO2-) formation. Reverse transcription-polymerase chain reaction (RT-PCR), revealed that all lines (SW480, SW620, DLD-1 and WiDr) expressed mRNA for the Ca(2+)-dependent endothelial (e)NOS, while SW480 cells also expressed the Ca(2+)-dependent neuronal (n)NOS. The mRNA for the Ca(2+)-independent inducible (i)NOS was expressed both by cytokine-stimulated and by unstimulated SW480, SW620 and DLD-1 cells, but none was seen at any time in the WiDr cells. There was, however, little correlation between mRNA expression and enzymic activity based on citrulline and NO2- formation. Thus none of the cell lines exhibited measurable Ca(2+)-dependent NOS activity, while Ca(2+)-independent NOS activity was seen in all but the WiDr cells. Furthermore, DLD-1 cells generated citrulline with resultant NO2- formation only after stimulation with lipopolysaccharide (LPS) and/or cytokines, while SW480 and SW620 did so constitutively. Thus RT-PCR studies indicate that tumour cells of similar epithelial origin display a diverse pattern of NOS gene family expression, and parallel biochemical studies clearly indicate that such expression does not always result in measurable enzymic activity leading to the generation of NO. Images Figure 1 Figure 2
Article
Full-text available
The nitric oxide synthases (NOS) are a family of related enzymes which regulate the production of NO, a free radical gas implicated in a wide variety of biological processes. Vasodilation and increased tumor blood flow, increased vascular permeability, modulation of host tumoricidal activity, and free radical injury to tumor cells and adjacent normal tissues are pathophysiological features of malignant tumors that may be mediated by NO. We examined human brain tumors for three NOS isoforms and NADPH diaphrase, a histochemical marker of NOS activity in the brain. We detected increased expression of the brain and endothelial forms of NOS [NOS I and NOS II, respectively (C. Nathan and Q. Xie. Cell, 78: 915-919, 1994)] in astrocytic tumors, and the highest levels of expression was found in higher grade tumors. Each of these two isoforms was found in tumor cells and tumor endothelial cells. The macrophage isoform of NOS (NOS III) was less frequently detected and expressed at a lower level, predominantly in tumor endothelial cells. NADPH diaphorase staining for NOS activity paralleled this pattern of NOS expression. Western blot analysis of tumor tissues for these NOS isoforms confirmed these observations. Our data indicate that malignant central nervous system neoplasms express unexpectedly high levels of NOS and suggest that NO production may be associated with pathophysiological processes important to these tumors.
Article
Full-text available
A subclone of the human colon adenocarcinoma cell line DLD-1, which grew reproducibly as subcutaneous tumors in nude mice, was isolated. Such cells, when engineered to generate nitric oxide (NO) continuously, grew more slowly in vitro than the wild-type parental cells. This growth retardation was reversed by the addition of N-iminoethyl-L-ornithine. In nude mice, however, the tumors from these cells grew faster than those derived from wild-type cells and were markedly more vascularized, suggesting that NO may act as part of a signaling cascade for neovascularization. Recent observations that the generation of NO in human breast and gynecological cancers correlates positively with tumor grade are consistent with this hypothesis. We suggest that NO may have a dual pro- and antitumor action, depending on the local concentration of the molecule.
Article
Full-text available
We recently reported development of an experimental model for the study of nitric oxide (NO.) toxicology in vivo. SJL mice were injected with superantigen-bearing RcsX (pre-B-cell lymphoma) cells, which migrated to the spleen and lymph nodes, where their rapid growth induced activation of macrophages to produce large amounts of NO. over a period of several weeks. In the experiments described here, we used this model to investigate mutagenesis in splenocytes exposed to NO. during RcsX cell growth. Transgenic mice were produced by crossbreeding animals of the pUR288 transgenic C57BL/6 and SJL strains. RcsX cells were injected into F1 mice and NO. production was confirmed by quantification of urinary nitrate, the ultimate metabolite of NO. Mutant frequency in the lacZ gene of the pUR288 plasmid was determined in DNA isolated from spleen (target) and kidney (nontarget) tissues. A significant elevation in mutant frequency was found in the spleen, but not in the kidney, of tumor-bearing mice. Furthermore, increases in mutant frequency in the spleen as well as NO. production were abrogated by administration of N-methylarginine, a NO. inhibitor, to mice following injection of RcsX cells. These results indicate that NO. had mutagenic activity in RcsX tumor-bearing mice and thus support a possible role for its involvement in the carcinogenic process.
Article
Endothelium-derived relaxing factor (EDRF) is a labile humoral agent which mediates the action of some vasodilators. Nitrovasodilators, which may act by releasing nitric oxide (NO), mimic the effect of EDRF and it has recently been suggested by Furchgott that EDRF may be NO. We have examined this suggestion by studying the release of EDRF and NO from endothelial cells in culture. No was determined as the chemiluminescent product of its reaction with ozone. The biological activity of EDRF and of NO was measured by bioassay. The relaxation of the bioassay tissues induced by EDRF was indistinguishable from that induced by NO. Both substances were equally unstable. Bradykinin caused concentration-dependent release of NO from the cells in amounts sufficient to account for the biological activity of EDRF. The relaxations induced by EDRF and NO were inhibited by haemoglobin and enhanced by superoxide dismutase to a similar degree. Thus NO released from endothelial cells is indistinguishable from EDRF in terms of biological activity, stability, and susceptibility to an inhibitor and to a potentiator. We suggest that EDRF and NO are identical.
Article
This review has identified several general themes in tumor biology that indicate directions requiring research emphasis in the future: 1. A more thorough understanding of the cellular and metabolic characteristics of tumors in humans in relation to laboratory models. Development of appropriate experimental models for studying questions of relevance to human tumors is important. 2. The significance of differences of intrinsic cellular sensitivity for determining tumor control and response to radiation therapy. The sensitivity of the clonogenic stem cells and the relative importance of their growth status at the time of treatment and subsequently, their repair capacity, and effects of local extrinsic pathophysiological microenvironments such as hypoxia need to be determined for human tumors. 3. Improvements of noninvasive methods to measure various pathophysiological and metabolic indicators of tumor response to therapy. An emphasis on studies that relate measurements obtained with invasive techniques to those obtained noninvasively is necessary to interpret and appropriately use the information to improve therapy. Many of these research areas require long-term studies and commitments both by investigators and funding support agencies to understand basic mechanisms as well as to develop and characterize appropriate models and new technologies as applied to studies of human tumors. For many of the scientific questions posed there is an opportunity to apply new molecular biology approaches so that significant differences in tumor genetic and phenotypic properties and changes associated with progression of malignancy can be identified at a level of sensitivity not previously possible. Such information may then be applied to develop ways to intervene therapeutically and improve cancer control rates in humans.